Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults
Sponsor: BeOne Medicines
Summary
The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet containing zanubrutinib and sonrotoclax (BG-71332) compared to a zanubrutinib capsule and sonrotoclax tablet administered simultaneously and the effect of food on how the body processes the fixed-dose combination tablet.
Official title: A Phase 1, Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Participants to Evaluate Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332)
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-09-24
Completion Date
2026-02-23
Last Updated
2026-04-20
Healthy Volunteers
Yes
Conditions
Interventions
BG-71332
Administered orally
Zanubrutinib
Administered orally
Sonrotoclax
Administered orally
Locations (1)
Linear Early Phase
Joondalup, Western Australia, Australia